Roflumilast
Who holds supplier records for Roflumilast? 13 organisations hold a current record for Roflumilast: an active US FDA Type II Drug Master File. Recorded organisation countries for current records: India (7), China (1), Peru (1), Taiwan (1) and 1 other country (1); not recorded for 2.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Roflumilast: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/roflumilast
Reading the evidence
- 13 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- Most recorded organisations are in India
7 of the 11 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.
- 7 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Roflumilast expires 19 Aug 2042. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (13)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Roflumilast. Country is the organisation's recorded country, not necessarily the manufacturing site.
- ALIVUS LIFE SCIENCES LTDIndia Company GMP cert on recordActive DMF 39781 · latest filing Mar 2024
- ALP PHARM BEIJING CO LTDActive DMF 27779 · latest filing Mar 2014
- APITORIA PHARMA PRIVATE LTDIndia Company GMP cert on recordActive DMF 32851 · latest filing Jun 2018
- CHONGQING HUAPONT PHARMACEUTICAL CO LTDActive DMF 28506 · latest filing Jul 2014
- HEFEI TIANRUI PHARMACEUTICAL CHEMICAL CO LTDChinaActive DMF 39317 · latest filing Dec 2023
- Hetero Drugs LimitedIndia Company GMP cert on recordActive DMF 28516 · latest filing Aug 2014
- INTERQUIM SAPeru Company GMP cert on recordActive DMF 28471 · latest filing Jul 2014
- MATRIX PHARMACORP PRIVATE LTDIndiaActive DMF 28440 · latest filing Sept 2014
- MSN Laboratories Private LimitedIndia Company GMP cert on recordActive DMF 27612 · latest filing Nov 2013
- SCINOPHARM TAIWAN LTDTaiwanActive DMF 26764 · latest filing Dec 2012
- Torrent PharmaceuticalsIndia Company GMP cert on recordActive DMF 35661 · latest filing Mar 2021
- VERANOVA LPUnited KingdomActive DMF 32093 · latest filing Oct 2017
- Zydus Lifesciences LimitedIndia Company GMP cert on recordActive DMF 28657 · latest filing Oct 2014
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (23 listed products contain Roflumilast). The latest listed patent expires 19 Aug 2042. The latest listed exclusivity runs to 29 Jun 2029. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Overview
Roflumilast is a selective phosphodiesterase 4 (PDE4) inhibitor that is used for the maintenance treatment of severe chronic obstructive pulmonary disease (COPD) to reduce the risk of exacerbations. It works by reducing inflammation in the lungs to improve breathing.
Chemical identity
- IUPAC name
- 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide
- Canonical SMILES
- C1CC1COC2=C(C=CC(=C2)C(=O)NC3=C(C=NC=C3Cl)Cl)OC(F)F
- InChIKey
- MNDBXUUTURYVHR-UHFFFAOYSA-N
- Synonyms
- Daliresp API, arq-151, arq-154 (roflumilast foam), b-9302-107, b9302-107, by-217, by217, byk-20869, byk20869, daliresp, daxas, zoryve
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Phosphodiesterase 4 Inhibitor
- Mechanism of action
- Phosphodiesterase 4 Inhibitors
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Roflumilast?
13 organisations hold an active US FDA Type II Drug Master File or a CEP for Roflumilast: ALIVUS LIFE SCIENCES LTD (India), ALP PHARM BEIJING CO LTD, APITORIA PHARMA PRIVATE LTD (India), CHONGQING HUAPONT PHARMACEUTICAL CO LTD, HEFEI TIANRUI PHARMACEUTICAL CHEMICAL CO LTD (China), Hetero Drugs Limited (India), INTERQUIM SA (Peru) and MATRIX PHARMACORP PRIVATE LTD (India), and 5 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Roflumilast Drug Master Files are active?
ALIVUS LIFE SCIENCES LTD (DMF 39781), ALP PHARM BEIJING CO LTD (DMF 27779), APITORIA PHARMA PRIVATE LTD (DMF 32851), CHONGQING HUAPONT PHARMACEUTICAL CO LTD (DMF 28506), HEFEI TIANRUI PHARMACEUTICAL CHEMICAL CO LTD (DMF 39317), Hetero Drugs Limited (DMF 28516), INTERQUIM SA (DMF 28471) and MATRIX PHARMACORP PRIVATE LTD (DMF 28440) and 5 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
Does the FDA Orange Book list patents for products containing Roflumilast?
Yes. The latest patent listed for an approved US product containing Roflumilast expires 19 Aug 2042, across 23 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Roflumilast supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Roflumilast?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.